Contents

Search


venglustat; ibiglustat

Contraindications: - treatment of GBA1-associated Parkinson's disease Mechanism of action: - brain-penetrant glucosylceramide synthase inhibitor

General

neurologic agent

Database Correlations

PUBCHEM correlations

References

  1. Giladi N et al. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: An international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2023 Aug; 22:661. PMID: 37479372 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00205-3/fulltext